Last updated: September 5, 2026
Tigecycline is a mature intravenous glycylcycline antibiotic with limited commercial growth potential. Pfizer’s Tygacil established the market after FDA approval in 2005, but core exclusivity ended in 2016 and multiple generic manufacturers now supply tigecycline injection. Revenue declined as hospital buyers shifted toward lower-cost generics and competing antibiotics. The product retains clinical value for selected complicated intra-abdominal, complicated skin and skin-structure, and community-acquired bacterial pneumonia infections, but its boxed warning, intravenous-only administration, broad-spectrum stewardship concerns, and lack of activity against key pathogens restrict demand. [1]
What is the current FDA status of tigecycline?
Tigecycline is FDA-approved as Tygacil and as generic tigecycline for injection.
| Regulatory item |
Status |
| Active ingredient |
Tigecycline |
| Original brand |
Tygacil |
| Original sponsor |
Wyeth Pharmaceuticals |
| Current originator owner |
Pfizer |
| FDA approval date |
June 15, 2005 |
| Dosage form |
Intravenous infusion |
| Common vial strength |
50 mg |
| Drug class |
Glycylcycline antibacterial |
| NDA |
021821 |
| FDA pathway |
New drug application, followed by abbreviated new drug applications |
| Current market structure |
Brand and generic injectable products |
| FDA boxed warning |
Increased all-cause mortality |
| Oral formulation |
Not approved |
| Biosimilar pathway |
Not applicable; tigecycline is a small-molecule drug |
The FDA approved tigecycline for complicated intra-abdominal infections and complicated skin and skin-structure infections. The indication was later expanded to include community-acquired bacterial pneumonia. The prescribing information warns that tigecycline should not be used for hospital-acquired or ventilator-associated pneumonia because clinical trial results showed lower cure rates and higher mortality in those settings. [1]
Tigecycline is not a biologic, so biosimilar competition does not apply. Generic manufacturers compete through the ANDA pathway, which relies on pharmaceutical equivalence and bioequivalence rather than clinical development comparable to a new drug application.
What patents protected Tygacil and when did tigecycline lose exclusivity?
The principal composition-of-matter protection for tigecycline expired in 2016. FDA chemical exclusivity began with the 2005 approval, while the five-year new chemical entity period ended in 2010. Pediatric exclusivity and patent terms extended commercial protection beyond the initial NCE period, but the principal market barrier ended in the middle of the decade.
| Protection category |
Approximate end point |
Commercial effect |
| FDA five-year NCE exclusivity |
2010 |
Delayed ANDA filing |
| Core composition patent |
2016 |
Protected the principal active ingredient |
| Pediatric extension and related protection |
2016 |
Extended the effective protected period |
| Generic entry window |
2016 onward |
Enabled ANDA competition |
| Current product position |
Post-exclusivity |
Generic injectable market |
The core U.S. patent commonly associated with tigecycline is U.S. Patent No. 5,494,903, covering glycylcycline compounds and related antibacterial agents. The patent’s effective protection ended in 2016 after applicable statutory adjustments and exclusivity considerations. Later patents covering manufacturing processes, intermediates, formulations, or specific uses did not recreate broad, product-level exclusivity for the drug.
How strong is the tigecycline patent estate?
The current patent estate is commercially weak as a barrier to generic entry.
Tigecycline’s core molecule is no longer protected by a live composition patent in the United States. Any remaining patent rights are more likely to concern process technology, crystalline forms, manufacturing controls, or narrow uses. Those rights can affect a specific supplier but generally do not prevent the market from supplying the active ingredient through alternative processes.
The product has no patent profile comparable to a recently approved branded antibiotic with active composition, formulation, and method-of-use patents. The main commercial defenses are manufacturing reliability, hospital contracting, regulatory compliance, and supply continuity.
How many patents cover tigecycline today?
The answer depends on the jurisdiction and the definition of a relevant patent. The broad U.S. composition protection has expired, while narrower patent families may remain in force in some markets.
The commercially relevant patent categories are:
- Core glycylcycline composition patents, largely expired.
- Synthetic intermediates and manufacturing processes.
- Pharmaceutical compositions and lyophilized injectable formulations.
- Dosage and administration methods.
- Narrow treatment methods involving selected resistant pathogens or dosing conditions.
These categories do not create a single, unified blocking estate. A generic manufacturer can often avoid a process or formulation patent by using a different synthesis route or formulation strategy.
What is the Orange Book status of tigecycline?
Tygacil is an older FDA-listed prescription product with generic equivalents. The Orange Book remains relevant for identifying the reference listed drug and any patents or exclusivity associated with the original NDA, but current market protection is not driven by an unexpired core patent.
Tigecycline’s Orange Book profile has several commercial implications:
- The reference product is Tygacil.
- Generic tigecycline injection can be approved through ANDAs.
- The product is not protected by biologic reference-product exclusivity.
- Any historical patent certifications are no longer a material barrier to broad generic supply.
- Method-of-use restrictions may be narrower than the full FDA label and do not generally preserve brand-wide exclusivity.
A Paragraph IV challenge would have been most commercially relevant before 2016. After expiration of the central patent position, ANDA competition became a standard post-exclusivity event rather than a high-value litigation trigger.
Which companies are challenging or competing with Tygacil?
The competitive set includes generic tigecycline suppliers and branded antibiotics used in overlapping hospital settings.
Generic tigecycline manufacturers
FDA-approved or historically marketed suppliers have included companies such as:
- Fresenius Kabi
- Hikma Pharmaceuticals
- Dr. Reddy’s Laboratories
- Teva Pharmaceuticals
- Sagent Pharmaceuticals
- Apotex and other ANDA sponsors
The active supplier roster can change because of manufacturing-site changes, shortages, acquisitions, product discontinuations, and procurement contracts. Generic competition is primarily price-based, but hospital buyers also evaluate sterility assurance, delivery reliability, vial availability, and shortage history.
Branded and alternative antibiotics
| Product |
Company or originator |
Main competitive distinction |
| Tygacil and generic tigecycline |
Pfizer and generic suppliers |
Broad spectrum, IV-only, low-cost mature product |
| Eravacycline, Xerava |
Tetraphase, acquired by La Jolla and later relevant commercial partners |
IV fluorocycline for complicated intra-abdominal infections |
| Omadacycline, Nuzyra |
Paratek |
IV and oral options for selected community infections |
| Linezolid, Zyvox and generics |
Pfizer and generic suppliers |
MRSA and resistant gram-positive coverage, oral step-down |
| Vancomycin |
Multiple suppliers |
Standard gram-positive coverage, including MRSA |
| Carbapenems |
Multiple suppliers |
Broad hospital-spectrum coverage |
| Beta-lactam/beta-lactamase inhibitors |
Multiple companies |
Increasingly used for resistant gram-negative infections |
Tigecycline’s broad coverage is offset by limited serum concentrations, gastrointestinal adverse effects, mortality concerns, and lack of reliable activity against Pseudomonas aeruginosa. These factors have narrowed its use despite its spectrum.
What is the financial trajectory of tigecycline?
Tigecycline followed a conventional mature-antibiotic trajectory:
- Initial branded growth after the 2005 launch.
- Revenue pressure after safety concerns and stewardship restrictions.
- Decline following patent expiry and generic entry.
- Conversion from a branded product to a low-price hospital injectable.
- Reduced strategic importance to Pfizer.
Pfizer historically reported Tygacil revenue in its product-level disclosures, but the company did not maintain a consistently detailed standalone revenue series after the product matured and generic competition expanded. Pfizer’s broader Essential Health and Established Products reporting made it difficult to isolate current Tygacil sales from related portfolio products. [2]
No reliable current standalone revenue figure should be inferred from Pfizer’s consolidated anti-infectives or established-products revenue. Current tigecycline sales are distributed among Pfizer, generic manufacturers, wholesalers, group purchasing organizations, and hospitals.
What drove the decline in Tygacil revenue?
The main drivers were:
- Loss of core patent protection in 2016.
- Entry of multiple ANDA-approved suppliers.
- Hospital purchasing substitution toward lower-priced generics.
- The 2010 FDA boxed warning regarding increased all-cause mortality. [3]
- Reduced use in hospital-acquired and ventilator-associated pneumonia.
- Antimicrobial stewardship programs favoring narrower or pathogen-directed therapy.
- Competition from newer agents with oral dosing, improved tolerability, or more targeted resistant-pathogen activity.
- Hospital price negotiations and group purchasing organization contracts.
The boxed warning did not remove tigecycline from the market, but it changed prescribing behavior and reduced its use for severe systemic infections where alternatives were available.
What revenue exposure does tigecycline create for Pfizer?
Tigecycline is no longer a material growth driver for Pfizer. Its commercial value is more consistent with a mature established product than a strategic innovation asset.
Revenue exposure is concentrated in:
- U.S. and international hospital injectable procurement.
- Generic and branded price spreads.
- Manufacturing and supply continuity.
- Existing hospital formulary placement.
- Residual brand loyalty among institutions using Tygacil.
The product does not provide meaningful pipeline optionality because its principal value is commercial supply, not new indication expansion. A serious manufacturing interruption could create temporary price increases or shortages, but that would be a supply event rather than durable franchise growth.
What generic entry risks exist for tigecycline?
Generic entry risk is high because the molecule is mature, the principal patent protection has expired, and the dosage form is a conventional injectable product.
Generic launch scenarios
| Scenario |
Probability assessment |
Market effect |
| Stable multi-supplier generic market |
High |
Persistent price compression and fragmented share |
| Supplier exit after low margins |
Moderate |
Temporary shortage risk and price volatility |
| Pfizer brand retention as a premium supplier |
Low to moderate |
Limited institutional demand for branded supply |
| New formulation-led resurgence |
Low |
Requires meaningful clinical or operational advantage |
| Manufacturing disruption |
Moderate over time |
Short-term allocation pressure and higher contract prices |
The main risk to incumbent suppliers is not patent litigation. It is loss of volume through hospital tenders, distributor substitution, and lower generic pricing.
What manufacturing and intellectual-property barriers remain?
Tigecycline manufacturing requires control of a complex tetracycline-derived structure, sterile injectable production, stability management, and compliance with current good manufacturing practice requirements. These factors can limit the number of dependable suppliers even when patent barriers are weak.
The practical barriers include:
- Consistent synthesis of the active pharmaceutical ingredient.
- Control of degradation products and impurities.
- Sterile filling and lyophilization or powder handling.
- Validation of reconstitution and infusion stability.
- Compliance at active-ingredient and finished-dose manufacturing sites.
- Reliable supply of specialized intermediates.
- FDA inspection readiness.
- Maintaining supply during hospital tenders at low prices.
These manufacturing barriers support occasional supply tightness but do not generally support premium pricing over an extended period.
What litigation and settlement agreements affect tigecycline?
Tigecycline’s most important litigation window was the period surrounding ANDA entry before and around patent expiry. The commercial effect of that period has largely passed.
There is no current strategic value in assuming that a historical Paragraph IV dispute can preserve broad exclusivity after expiry of the core patent. Any remaining litigation would more likely involve:
- Patent ownership or inventorship.
- Manufacturing processes.
- Product liability.
- FDA compliance.
- Shortage-related supply obligations.
- Contract disputes between suppliers and purchasers.
No widely reported active settlement has preserved a broad U.S. market monopoly for Tygacil. The post-2016 market is defined by generic competition rather than by a continuing patent settlement structure.
How does tigecycline compare with eravacycline and omadacycline?
| Attribute |
Tigecycline |
Eravacycline |
Omadacycline |
| Commercial status |
Mature generic market |
Branded specialty product |
Branded specialty product with generic pressure risk |
| Administration |
IV only |
IV |
IV and oral |
| Primary positioning |
Complicated intra-abdominal and selected other infections |
Complicated intra-abdominal infections |
Community-acquired bacterial pneumonia and skin infections |
| Patent position |
Largely expired |
Newer active patent estate |
Newer active patent estate |
| Price position |
Low-cost |
Premium |
Premium |
| Main limitation |
Mortality warning, nausea, IV-only use |
Cost and hospital adoption |
Cost and uptake |
| Generic risk |
High and established |
Lower than tigecycline |
Depends on patent and regulatory status |
| Commercial growth |
Limited |
Specialty-market dependent |
Dependent on oral adoption and payer access |
Tigecycline remains competitive when a hospital needs broad coverage at a low acquisition cost and the clinical setting fits its label. It is less competitive when oral therapy, serum exposure, lower gastrointestinal toxicity, or resistant gram-negative targeting is the priority.
What is the geographic coverage of tigecycline protection?
Patent protection expired at different times across jurisdictions because national patent terms, supplementary protection certificates, pediatric extensions, and regulatory exclusivities vary. The United States and major European markets moved into generic competition after the core protection period. Emerging-market generic competition can be broader, but local registration, procurement rules, and manufacturing controls determine actual availability.
Commercially, the product is most exposed to generic substitution in:
- The United States.
- Western Europe.
- Japan and other highly regulated markets.
- Hospital markets with centralized procurement.
- Countries with established local injectable manufacturing.
In lower-income markets, supply may be less predictable because procurement is highly price sensitive and the number of qualified sterile manufacturers can be limited.
What is the outlook for tigecycline through 2030?
Tigecycline is likely to remain a stable but declining hospital antibiotic rather than a growth product.
The base-case outlook is:
- Continued generic price pressure.
- Low probability of broad new indication expansion.
- Periodic supply disruptions from sterile manufacturing constraints.
- Stable use in selected complicated infections.
- Further displacement in settings where newer fluorocyclines, oral agents, or targeted therapies are available.
- Limited value from additional patent filings unless they protect a clearly differentiated formulation or treatment method.
The strongest commercial opportunity is not a premium branded relaunch. It is dependable, low-cost supply supported by regulatory-compliant manufacturing and hospital contracting.
Key Takeaways
- Tigecycline was approved by the FDA in 2005 as Tygacil.
- The product is an IV-only glycylcycline antibiotic.
- Its core U.S. patent protection ended in 2016.
- Generic entry is established, and biosimilar competition is irrelevant because tigecycline is a small molecule.
- The FDA boxed warning for increased mortality materially constrained use in severe hospital infections.
- Pfizer no longer treats tigecycline as a material growth asset.
- Current competition centers on generic price, supply reliability, and hospital contracts.
- Manufacturing quality and sterile supply capacity are more important than broad patent protection.
- Tigecycline’s long-term market is likely to be mature, low-growth, and vulnerable to substitution by newer or more convenient antibiotics.
FAQs
Is tigecycline still under patent protection?
The core U.S. composition protection expired in 2016. Narrow process, formulation, or method patents may exist in certain jurisdictions, but they do not provide broad product exclusivity.
Can a generic company launch tigecycline without conducting new clinical trials?
Yes. A company can generally seek FDA approval through an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product, subject to applicable patent certifications and regulatory requirements.
Does tigecycline have biosimilar competition?
No. Tigecycline is a synthetic small-molecule drug. Its competitors are generic versions approved through the ANDA pathway.
Why is tigecycline avoided for ventilator-associated pneumonia?
The FDA label states that tigecycline should not be used for hospital-acquired or ventilator-associated pneumonia because trials showed lower cure rates and increased mortality in those settings. [1]
Could tigecycline prices rise despite patent expiry?
Yes. Prices can rise temporarily if sterile injectable manufacturers exit, experience quality problems, or face shortages. Patent expiry still limits sustained premium pricing because alternative suppliers can enter or expand production.
References
- U.S. Food and Drug Administration. (2024). Tygacil (tigecycline) prescribing information. FDA. https://www.accessdata.fda.gov
- Pfizer Inc. (2017). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Pfizer. https://www.pfizer.com/investor
- U.S. Food and Drug Administration. (2010). FDA drug safety communication: Increased risk of death with Tygacil compared to other antibiotics used to treat serious infections. FDA. https://www.fda.gov/drugs/drug-safety-and-availability
